The Wegovy multidose pen: how it works and what the evidence says

What the STEP programme established about the multidose format

The evidence base for Wegovy was built using exactly this delivery format. In STEP 1 (a 68-week randomised trial published in the New England Journal of Medicine) adults with obesity injecting 2.4 mg semaglutide weekly achieved an average body-weight reduction of around 15% compared with roughly 2.5% in the placebo group. Those results came from consistent weekly dosing using the same pre-filled multidose pen design that reaches UK patients today, and if you want to understand that device in detail, our guide to the Wegovy multi-use pen explains how it is constructed and how each dose is delivered. Knowing the delivery method was held constant throughout STEP 1 matters: technique errors, missed doses, and incorrect storage were controlled for in the trial setting. In real-world use, they often are not. The pen itself is straightforward to use, but there is a short list of things that genuinely change what you get out of it, and they are worth understanding before your first injection.

The NHS semaglutide medicines page summarises the key practical steps alongside official guidance on side effects and storage. It is a useful first read before you pick up your pen.

How the four doses in one pen actually work, and where people go wrong

The multidose pen has a fixed dose selector. You do not set the dose yourself; the pen is pre-calibrated to the strength printed on its label. Each time you complete an injection and the plunger advances, one of the four doses is used. The dose counter visible on the side tells you exactly how many remain. That quick check before every injection (two seconds, no more) is the kind of habit that catches a nearly-empty pen before you find out mid-injection.

The most common technical errors reported to clinicians are needle-related rather than pen-related. Reusing a needle blunts the tip, increases injection-site pain, and risks a clog that means the dose is not fully delivered. A fresh needle for each injection is not optional. If you are setting up for the first time or want a step-by-step walkthrough of the process, our guide to using the Wegovy pen covers priming, site selection, and what to do if something does not look right.

Injection sites are the abdomen, thigh, or upper arm; rotating between them each week reduces localised skin reactions. Pinching a small fold of skin, inserting the needle at a 90-degree angle, and pressing the injection button until the dose counter moves to the next number are the core steps. Hold for six seconds after the button click before withdrawing, this prevents solution leaking back out.

Storage, travel, and the needle-change question

The pen lives in the fridge between injections. The Patient Information Leaflet states the permitted room-temperature window precisely; that figure is the authority, not any number you may see quoted online. For cost context around treatment, our Wegovy cost guide sets out what private prescriptions typically include. If you are travelling and need to keep the pen cool, a purpose-built cool pouch works well; the pen should never be frozen, and it should never be left in direct sunlight or a hot car.

Used needles are clinical waste. A sharps container is the correct disposal route; many GP practices and pharmacies accept full containers. Do not recap needles and do not put them in household bins.

People sometimes ask whether the multidose pen can be used to take less than the prescribed dose on a given week, so-called microdosing. The pen is not designed for that. The clinical position on microdosing the Wegovy pen is clear: dose adjustments are a prescriber decision, made through the formal titration schedule, not a technique to improvise at home. If the prescribed dose is causing side effects you cannot manage, contact your prescriber before changing anything.

The 7.2 mg pen: a different format, same weekly rhythm

In April 2026 the MHRA approved a dedicated single-dose 7.2 mg Wegovy pen, one weekly injection, a single pre-set dose, auto-locking after use, and you can read a full breakdown of how it differs from the multidose device on our Wegovy pen page. It is a separate device from the multidose pen, designed for people who have titrated up through the standard schedule and whose prescriber moves them to this higher maintenance dose. Trials at the 7.2 mg dose reported average weight loss of around 20.7% over 72 weeks, approaching the results seen with tirzepatide at its highest dose. For background on how Wegovy compares to other weight-loss injections currently available in the UK, the Wegovy overview page covers the licensed options and the evidence behind them.

Suitability for the 7.2 mg pen (including which pen format your dose is supplied in) is confirmed at consultation. If you are already on treatment with another provider and want to continue or change dose, our prescribers review transfer patients the same day. Speak to our prescribers to start that process.